PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21501118-2 2011 HLA-B*5701 is strongly associated with hypersensitivity to the HIV drug abacavir, liver toxicity from the antibiotic flucloxacillin and is a marker for slow progression of HIV AIDS. Floxacillin 117-131 major histocompatibility complex, class I, B Homo sapiens 0-5 32726429-0 2020 Identification of flucloxacillin-haptenated HLA-B*57:01 ligands: evidence of antigen processing and presentation. Floxacillin 18-32 major histocompatibility complex, class I, B Homo sapiens 44-49 19483685-0 2009 HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Floxacillin 79-93 major histocompatibility complex, class I, B Homo sapiens 0-5 19483685-5 2009 Further MHC genotyping, which included 64 flucloxacillin-tolerant controls, confirmed the association with HLA-B*5701 (OR = 80.6, P = 9.0 x 10(-19)). Floxacillin 42-56 major histocompatibility complex, class I, B Homo sapiens 107-112 32726429-4 2020 In this study, the binding of flucloxacillin to immune cells was characterized and the nature of the peptides presented by human leukocyte antigen HLA-B*57:01 was analyzed using mass spectrometric based immunopeptidomics methods. Floxacillin 30-44 major histocompatibility complex, class I, B Homo sapiens 147-152 32726429-6 2020 Of the peptides eluted from flucloxacillin-treated C1R-B*57:01 cells, 6 putative peptides were annotated as flucloxacillin-modified HLA-B*57:01 peptide ligands (Data are available via ProteomeXchange with identifier PXD020137). Floxacillin 28-42 major histocompatibility complex, class I, B Homo sapiens 132-137 32726429-6 2020 Of the peptides eluted from flucloxacillin-treated C1R-B*57:01 cells, 6 putative peptides were annotated as flucloxacillin-modified HLA-B*57:01 peptide ligands (Data are available via ProteomeXchange with identifier PXD020137). Floxacillin 108-122 major histocompatibility complex, class I, B Homo sapiens 132-137 32130375-0 2020 Flucloxacillin-Induced Hepatotoxicity - Association with HLA-B*5701. Floxacillin 0-14 major histocompatibility complex, class I, B Homo sapiens 57-62 32130375-13 2020 The authors present this case to remind the possibility of moderate/severe drug-induced liver injury to flucloxacillin, an antibiotic commonly used in clinical practice and association with the HLA-B * 5701 allele reported in the literature. Floxacillin 104-118 major histocompatibility complex, class I, B Homo sapiens 194-199 29436218-4 2018 Weak flucloxacillin-specific T cell responses were detected in donors expressing HLA-B*57:01 and HLA-B*58:01. Floxacillin 5-19 major histocompatibility complex, class I, B Homo sapiens 81-86 30538582-16 2018 Clinical risk factors for flucloxacillin-induced DILI could be used to indicate whom to test for HLA-B*57:01 before treatment. Floxacillin 26-40 major histocompatibility complex, class I, B Homo sapiens 97-102 30661239-2 2019 HLA-B*57:01 is an established genetic risk factor for flucloxacillin DILI. Floxacillin 54-68 major histocompatibility complex, class I, B Homo sapiens 0-5 29436218-4 2018 Weak flucloxacillin-specific T cell responses were detected in donors expressing HLA-B*57:01 and HLA-B*58:01. Floxacillin 5-19 major histocompatibility complex, class I, B Homo sapiens 97-102 28253087-5 2017 We found that the genetic risk variants that were identified genome-wide, and replication confirmed, are mainly related to polymorphisms in the human leukocyte antigen (HLA) region that include HLA-DQB1*06:02 for amoxicillin-clavulanate, HLA-B*57:01 for flucloxacillin, HLA-DRB1*15:01 for lumiracoxib, and HLA-DRB1*07:01 for lapatinib and ximelagatran-induced hepatotoxicity. Floxacillin 254-268 major histocompatibility complex, class I, B Homo sapiens 238-243 28346841-1 2017 HLA-B*57:01 is strongly associated with severe adverse drug reaction induced by the anti-HIV drug abacavir (ABC) and antibiotic flucloxacillin. Floxacillin 128-142 major histocompatibility complex, class I, B Homo sapiens 0-5 28346841-10 2017 The newly established real-time PCR assay provides a rapid and reliable tool for HLA-B*57:01 allele screening before the prescription of ABC and flucloxacillin in clinical practice. Floxacillin 145-159 major histocompatibility complex, class I, B Homo sapiens 81-86 28017537-2 2017 For example, it is well-established that HLA-B*15:02 and HLA-B*57:01 are associated with carbamazepine-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and abacavir-induced hypersensitivity/flucloxacillin-induced liver injury, respectively. Floxacillin 213-227 major histocompatibility complex, class I, B Homo sapiens 41-46 28017537-2 2017 For example, it is well-established that HLA-B*15:02 and HLA-B*57:01 are associated with carbamazepine-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and abacavir-induced hypersensitivity/flucloxacillin-induced liver injury, respectively. Floxacillin 213-227 major histocompatibility complex, class I, B Homo sapiens 57-62 28017537-6 2017 Finally, HLA-B*57:01-restricted activation of T-cells from patients with flucloxacillin-induced liver injury is dependent on processing of drug protein adducts. Floxacillin 73-87 major histocompatibility complex, class I, B Homo sapiens 9-14 27637899-8 2016 Furthermore, responses were detected to carbamazepine (in HLA-B*15:02 donors), flucloxacillin (in 1 HLA-B*57:01 donor) and oxypurinol (in HLA-B*58:01 donors), which are associated with HLA-class I-restricted forms of hypersensitivity. Floxacillin 79-93 major histocompatibility complex, class I, B Homo sapiens 100-105 28856081-4 2017 The presence of the HLA-B*57:01 allele has been associated with an 81-fold increased risk of flucloxacillin DILI. Floxacillin 93-107 major histocompatibility complex, class I, B Homo sapiens 20-25 27637899-8 2016 Furthermore, responses were detected to carbamazepine (in HLA-B*15:02 donors), flucloxacillin (in 1 HLA-B*57:01 donor) and oxypurinol (in HLA-B*58:01 donors), which are associated with HLA-class I-restricted forms of hypersensitivity. Floxacillin 79-93 major histocompatibility complex, class I, B Homo sapiens 100-105 24777842-7 2015 Interestingly, HLA-B*57:01 is associated with both abacavir DISI and flucloxacillin DILI but the reasons for the different phenotype of ADR remains unknown. Floxacillin 69-83 major histocompatibility complex, class I, B Homo sapiens 15-20 25080918-2 2014 Several HLA-B alleles proved to be associated with SADRs for drugs such as carbamazepine, allopurinol, lamotrigine, and flucloxacillin. Floxacillin 120-134 major histocompatibility complex, class I, B Homo sapiens 8-13 22987284-0 2013 Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Floxacillin 122-136 major histocompatibility complex, class I, B Homo sapiens 0-31 24731753-0 2014 T cells infiltrate the liver and kill hepatocytes in HLA-B(*)57:01-associated floxacillin-induced liver injury. Floxacillin 78-89 major histocompatibility complex, class I, B Homo sapiens 53-58 24731753-3 2014 Recent studies have identified the HLA-B(*)57:01 allele as a risk factor for floxacillin (FLUX)-induced liver injury and have suggested a role for cytotoxic CD8(+) T cells in the pathomechanism of liver injury caused by FLUX. Floxacillin 77-88 major histocompatibility complex, class I, B Homo sapiens 35-40 23596311-2 2013 A particularly interesting example is flucloxacillin (FLUX)-DILI, which is associated with the HLA-B*57:01 allele. Floxacillin 38-52 major histocompatibility complex, class I, B Homo sapiens 95-100 22987284-2 2013 For flucloxacillin, a delay in the reaction onset and identification of human leukocyte antigen (HLA)-B*57:01 as a susceptibility factor are indicative of an immune pathogenesis. Floxacillin 4-18 major histocompatibility complex, class I, B Homo sapiens 78-103 22987284-3 2013 Thus, we characterize flucloxacillin-responsive CD4+ and CD8+ T cells from patients with liver injury and show that naive CD45RA+CD8+ T cells from volunteers expressing HLA-B*57:01 are activated with flucloxacillin when dendritic cells present the drug antigen. Floxacillin 22-36 major histocompatibility complex, class I, B Homo sapiens 169-174 22987284-3 2013 Thus, we characterize flucloxacillin-responsive CD4+ and CD8+ T cells from patients with liver injury and show that naive CD45RA+CD8+ T cells from volunteers expressing HLA-B*57:01 are activated with flucloxacillin when dendritic cells present the drug antigen. Floxacillin 200-214 major histocompatibility complex, class I, B Homo sapiens 169-174 22987284-6 2013 Activation of CD8+ clones with flucloxacillin was processing-dependent and restricted by HLA-B*57:01 and the closely related HLA-B*58:01. Floxacillin 31-45 major histocompatibility complex, class I, B Homo sapiens 89-94 22987284-6 2013 Activation of CD8+ clones with flucloxacillin was processing-dependent and restricted by HLA-B*57:01 and the closely related HLA-B*58:01. Floxacillin 31-45 major histocompatibility complex, class I, B Homo sapiens 125-130 23032409-0 2013 The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. Floxacillin 14-28 major histocompatibility complex, class I, B Homo sapiens 68-73 23032409-1 2013 Positive HLA-B*5701 genotype has recently been identified as the main genetic risk factor for flucloxacillin drug-induced liver injury (DILI). Floxacillin 94-108 major histocompatibility complex, class I, B Homo sapiens 9-14 23032409-3 2013 Considering the high prevalence of soft-tissue infections in HIV patients, we conducted a retrospective study to investigate whether flucloxacillin use was associated with adverse events in HIV patients known to be HLA-B*5701 positive. Floxacillin 133-147 major histocompatibility complex, class I, B Homo sapiens 215-220